25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

TLX (Telix Pharmaceuticals Limited) Stock Analysis
Buy, Hold or Sell?

Let's analyze Telix Pharmaceuticals Limited together

I guess you are interested in Telix Pharmaceuticals Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Telix Pharmaceuticals Limited’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Telix Pharmaceuticals Limited’s Price Targets

I'm going to help you getting a better view of Telix Pharmaceuticals Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Telix Pharmaceuticals Limited

I send you an email if I find something interesting about Telix Pharmaceuticals Limited.

1. Quick Overview

1.1. Quick analysis of Telix Pharmaceuticals Limited (30 sec.)










1.2. What can you expect buying and holding a share of Telix Pharmaceuticals Limited? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$1.09
Expected worth in 1 year
$4.29
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
$3.20
Return On Investment
34.7%

For what price can you sell your share?

Current Price per Share
$9.21
Expected price per share
$8.93 - $12.60
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Telix Pharmaceuticals Limited (5 min.)




Live pricePrice per Share (EOD)
$9.21
Intrinsic Value Per Share
$-0.26 - $1.77
Total Value Per Share
$0.84 - $2.86

2.2. Growth of Telix Pharmaceuticals Limited (5 min.)




Is Telix Pharmaceuticals Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$377.9m$99m$278.9m73.8%

How much money is Telix Pharmaceuticals Limited making?

Current yearPrevious yearGrowGrow %
Making money$33.2m$3.4m$29.7m89.6%
Net Profit Margin6.4%1.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Telix Pharmaceuticals Limited (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#150 / 863

Most Revenue
#33 / 863

Most Profit
#55 / 863

Most Efficient
#135 / 863
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Telix Pharmaceuticals Limited?

Welcome investor! Telix Pharmaceuticals Limited's management wants to use your money to grow the business. In return you get a share of Telix Pharmaceuticals Limited.

First you should know what it really means to hold a share of Telix Pharmaceuticals Limited. And how you can make/lose money.

Speculation

The Price per Share of Telix Pharmaceuticals Limited is $9.21. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Telix Pharmaceuticals Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Telix Pharmaceuticals Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.09. Based on the TTM, the Book Value Change Per Share is $0.80 per quarter. Based on the YOY, the Book Value Change Per Share is $0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Telix Pharmaceuticals Limited.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.101.0%0.101.0%0.010.1%-0.03-0.4%-0.07-0.8%-0.04-0.5%
Usd Book Value Change Per Share0.808.7%0.808.7%0.131.4%0.363.9%0.192.1%0.111.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.010.1%
Usd Total Gains Per Share0.808.7%0.808.7%0.131.4%0.363.9%0.192.1%0.121.3%
Usd Price Per Share15.40-15.40-0.00-5.13-3.08-1.54-
Price to Earnings Ratio160.09-160.09-0.00-53.36-32.02-16.01-
Price-to-Total Gains Ratio19.27-19.27-19.27-19.27-19.27-
Price to Book Ratio14.06-14.06-0.00-4.69-2.81-1.41-
Price-to-Total Gains Ratio19.27-19.27-19.27-19.27-19.27-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.21
Number of shares108
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.800.19
Usd Total Gains Per Share0.800.19
Gains per Quarter (108 shares)86.3020.62
Gains per Year (108 shares)345.1982.46
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1034533508272
206906800165154
30103610250247236
40138113700330318
50172617150412400
60207120600495482
70241624050577564
80276227500660646
90310730950742728
100345234400825810

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%2.01.00.066.7%2.03.00.040.0%2.08.00.020.0%3.010.00.023.1%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%8.02.00.080.0%9.04.00.069.2%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%1.00.09.010.0%1.00.012.07.7%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%8.02.00.080.0%9.04.00.069.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Telix Pharmaceuticals Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.7990.7990%0.133+502%0.363+120%0.191+319%0.110+627%
Book Value Per Share--1.0951.0950%0.296+270%0.518+111%0.344+218%0.206+432%
Current Ratio--2.7762.7760%1.428+94%2.076+34%2.435+14%5.710-51%
Debt To Asset Ratio--0.6250.6250%0.6260%0.645-3%0.683-8%0.618+1%
Debt To Equity Ratio--1.6691.6690%1.6750%1.858-10%11.168-85%5.678-71%
Dividend Per Share----0%-0%-0%-0%0.011-100%
Enterprise Value--5157662745.6005157662745.6000%--5157662745.6000%5157662745.6000%5157662745.6000%
Eps--0.0960.0960%0.010+829%-0.033+135%-0.070+173%-0.045+146%
Ev To Ebitda Ratio--83.78083.7800%--83.7800%83.7800%83.7800%
Ev To Sales Ratio--9.9009.9000%--9.9000%9.9000%9.9000%
Free Cash Flow Per Share--0.0170.0170%0.026-33%-0.037+314%-0.046+364%-0.034+299%
Free Cash Flow To Equity Per Share--1.2491.2490%0.046+2599%0.496+152%0.289+332%0.153+714%
Gross Profit Margin---0.712-0.7120%-9.529+1238%-2.959+315%-1.355+90%-0.169-76%
Intrinsic Value_10Y_max--1.767----------
Intrinsic Value_10Y_min---0.258----------
Intrinsic Value_1Y_max--0.011----------
Intrinsic Value_1Y_min---0.041----------
Intrinsic Value_3Y_max--0.160----------
Intrinsic Value_3Y_min---0.111----------
Intrinsic Value_5Y_max--0.461----------
Intrinsic Value_5Y_min---0.167----------
Market Cap3082808040.000-72%5315895200.0005315895200.0000%-+100%1771965066.667+200%1063179040.000+400%531589520.000+900%
Net Profit Margin--0.0640.0640%0.010+515%-0.192+401%-3.957+6309%-9.886+15610%
Operating Margin--0.1050.1050%0.032+225%-0.159+251%-3.988+3903%-16.410+15749%
Operating Ratio--0.8950.8950%0.8980%1.084-17%5.079-82%26.477-97%
Pb Ratio8.411-67%14.06414.0640%-+100%4.688+200%2.813+400%1.406+900%
Pe Ratio95.741-67%160.088160.0880%-+100%53.363+200%32.018+400%16.009+900%
Price Per Share9.210-67%15.40015.4000%-+100%5.133+200%3.080+400%1.540+900%
Price To Free Cash Flow Ratio531.209-67%888.232888.2320%-+100%296.077+200%177.646+400%88.823+900%
Price To Total Gains Ratio11.526-67%19.27319.2730%--19.2730%19.2730%19.2730%
Quick Ratio--2.6272.6270%1.288+104%1.880+40%2.277+15%5.533-53%
Return On Assets--0.0330.0330%0.013+152%-0.118+458%-0.272+926%-0.195+691%
Return On Equity--0.0880.0880%0.035+151%-0.393+547%-7.811+8991%-3.984+4635%
Total Gains Per Share--0.7990.7990%0.133+502%0.363+120%0.191+319%0.121+561%
Usd Book Value--377975287.600377975287.6000%99055597.200+282%177227018.667+113%117463676.800+222%70103012.858+439%
Usd Book Value Change Per Share--0.7990.7990%0.133+502%0.363+120%0.191+319%0.110+627%
Usd Book Value Per Share--1.0951.0950%0.296+270%0.518+111%0.344+218%0.206+432%
Usd Dividend Per Share----0%-0%-0%-0%0.011-100%
Usd Enterprise Value--5157662745.6005157662745.6000%--5157662745.6000%5157662745.6000%5157662745.6000%
Usd Eps--0.0960.0960%0.010+829%-0.033+135%-0.070+173%-0.045+146%
Usd Free Cash Flow--5984804.4005984804.4000%8707468.000-31%-12360302.933+307%-15269399.920+355%-11508536.822+292%
Usd Free Cash Flow Per Share--0.0170.0170%0.026-33%-0.037+314%-0.046+364%-0.034+299%
Usd Free Cash Flow To Equity Per Share--1.2491.2490%0.046+2599%0.496+152%0.289+332%0.153+714%
Usd Market Cap3082808040.000-72%5315895200.0005315895200.0000%-+100%1771965066.667+200%1063179040.000+400%531589520.000+900%
Usd Price Per Share9.210-67%15.40015.4000%-+100%5.133+200%3.080+400%1.540+900%
Usd Profit--33206118.80033206118.8000%3466357.200+858%-10853624.933+133%-23194991.840+170%-14807081.929+145%
Usd Revenue--520989296.400520989296.4000%334294264.400+56%320593140.000+63%194059993.360+168%103493957.744+403%
Usd Total Gains Per Share--0.7990.7990%0.133+502%0.363+120%0.191+319%0.121+561%
 EOD+4 -4MRQTTM+0 -0YOY+26 -73Y+29 -45Y+29 -410Y+25 -10

3.3 Fundamental Score

Let's check the fundamental score of Telix Pharmaceuticals Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1595.741
Price to Book Ratio (EOD)Between0-18.411
Net Profit Margin (MRQ)Greater than00.064
Operating Margin (MRQ)Greater than00.105
Quick Ratio (MRQ)Greater than12.627
Current Ratio (MRQ)Greater than12.776
Debt to Asset Ratio (MRQ)Less than10.625
Debt to Equity Ratio (MRQ)Less than11.669
Return on Equity (MRQ)Greater than0.150.088
Return on Assets (MRQ)Greater than0.050.033
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Telix Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.186
Ma 20Greater thanMa 5010.516
Ma 50Greater thanMa 10012.666
Ma 100Greater thanMa 20014.836
OpenGreater thanClose9.160
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing TLX250-CDx, a positron emission tomography (PET) diagnostic imaging agent for the characterization of renal masses as clear cell renal cell carcinoma; TLX101-CDx, a PET diagnostic agent to image cancerous lesions in the brain; and TLX66-CDx, a cluster of differentiation 66 imaging agent for osteomyelitis (bone infection). It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Fundamental data was last updated by Penke on 2025-09-12 18:48:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Telix Pharmaceuticals Limited earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Telix Pharmaceuticals Limited to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 6.4%Β means thatΒ $0.06 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Telix Pharmaceuticals Limited:

  • The MRQ is 6.4%. The company is making a profit. +1
  • The TTM is 6.4%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ6.4%TTM6.4%0.0%
TTM6.4%YOY1.0%+5.3%
TTM6.4%5Y-395.7%+402.1%
5Y-395.7%10Y-988.6%+592.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4%-73.5%+79.9%
TTM6.4%-154.3%+160.7%
YOY1.0%-207.9%+208.9%
3Y-19.2%-272.9%+253.7%
5Y-395.7%-345.5%-50.2%
10Y-988.6%-504.5%-484.1%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Telix Pharmaceuticals Limited is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Telix Pharmaceuticals Limited to theΒ Biotechnology industry mean.
  • 3.3% Return on Assets means thatΒ Telix Pharmaceuticals Limited generatedΒ $0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Telix Pharmaceuticals Limited:

  • The MRQ is 3.3%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.3%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.3%TTM3.3%0.0%
TTM3.3%YOY1.3%+2.0%
TTM3.3%5Y-27.2%+30.5%
5Y-27.2%10Y-19.5%-7.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3%-11.8%+15.1%
TTM3.3%-11.6%+14.9%
YOY1.3%-11.0%+12.3%
3Y-11.8%-11.9%+0.1%
5Y-27.2%-11.5%-15.7%
10Y-19.5%-13.6%-5.9%
4.3.1.3. Return on Equity

Shows how efficient Telix Pharmaceuticals Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Telix Pharmaceuticals Limited to theΒ Biotechnology industry mean.
  • 8.8% Return on Equity means Telix Pharmaceuticals Limited generated $0.09Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Telix Pharmaceuticals Limited:

  • The MRQ is 8.8%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 8.8%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ8.8%TTM8.8%0.0%
TTM8.8%YOY3.5%+5.3%
TTM8.8%5Y-781.1%+789.9%
5Y-781.1%10Y-398.4%-382.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.8%-13.7%+22.5%
TTM8.8%-14.6%+23.4%
YOY3.5%-15.0%+18.5%
3Y-39.3%-16.4%-22.9%
5Y-781.1%-16.9%-764.2%
10Y-398.4%-19.0%-379.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Telix Pharmaceuticals Limited.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Telix Pharmaceuticals Limited is operatingΒ .

  • Measures how much profit Telix Pharmaceuticals Limited makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Telix Pharmaceuticals Limited to theΒ Biotechnology industry mean.
  • An Operating Margin of 10.5%Β means the company generated $0.10 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Telix Pharmaceuticals Limited:

  • The MRQ is 10.5%. The company is operating less efficient.
  • The TTM is 10.5%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ10.5%TTM10.5%0.0%
TTM10.5%YOY3.2%+7.3%
TTM10.5%5Y-398.8%+409.3%
5Y-398.8%10Y-1,641.0%+1,242.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.5%-153.1%+163.6%
TTM10.5%-247.8%+258.3%
YOY3.2%-244.8%+248.0%
3Y-15.9%-256.2%+240.3%
5Y-398.8%-340.5%-58.3%
10Y-1,641.0%-503.1%-1,137.9%
4.3.2.2. Operating Ratio

Measures how efficient Telix Pharmaceuticals Limited is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.90 means that the operating costs are $0.90 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Telix Pharmaceuticals Limited:

  • The MRQ is 0.895. The company is less efficient in keeping operating costs low.
  • The TTM is 0.895. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.895TTM0.8950.000
TTM0.895YOY0.898-0.003
TTM0.8955Y5.079-4.184
5Y5.07910Y26.477-21.398
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8951.859-0.964
TTM0.8952.752-1.857
YOY0.8982.941-2.043
3Y1.0843.642-2.558
5Y5.0794.701+0.378
10Y26.4776.681+19.796
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Telix Pharmaceuticals Limited.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Telix Pharmaceuticals Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 2.78Β means the company has $2.78 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Telix Pharmaceuticals Limited:

  • The MRQ is 2.776. The company is able to pay all its short-term debts. +1
  • The TTM is 2.776. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.776TTM2.7760.000
TTM2.776YOY1.428+1.347
TTM2.7765Y2.435+0.341
5Y2.43510Y5.710-3.276
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7763.457-0.681
TTM2.7763.689-0.913
YOY1.4284.093-2.665
3Y2.0764.571-2.495
5Y2.4355.722-3.287
10Y5.7106.137-0.427
4.4.3.2. Quick Ratio

Measures if Telix Pharmaceuticals Limited is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Telix Pharmaceuticals Limited to theΒ Biotechnology industry mean.
  • A Quick Ratio of 2.63Β means the company can pay off $2.63 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Telix Pharmaceuticals Limited:

  • The MRQ is 2.627. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.627. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.627TTM2.6270.000
TTM2.627YOY1.288+1.339
TTM2.6275Y2.277+0.350
5Y2.27710Y5.533-3.256
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6272.940-0.313
TTM2.6273.288-0.661
YOY1.2883.896-2.608
3Y1.8804.373-2.493
5Y2.2775.800-3.523
10Y5.5336.520-0.987
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Telix Pharmaceuticals Limited.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Telix Pharmaceuticals LimitedΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Telix Pharmaceuticals Limited to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.63Β means that Telix Pharmaceuticals Limited assets areΒ financed with 62.5% credit (debt) and the remaining percentage (100% - 62.5%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Telix Pharmaceuticals Limited:

  • The MRQ is 0.625. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.625. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.625TTM0.6250.000
TTM0.625YOY0.626-0.001
TTM0.6255Y0.683-0.058
5Y0.68310Y0.618+0.065
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6250.339+0.286
TTM0.6250.356+0.269
YOY0.6260.334+0.292
3Y0.6450.344+0.301
5Y0.6830.351+0.332
10Y0.6180.378+0.240
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Telix Pharmaceuticals Limited is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Telix Pharmaceuticals Limited to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 166.9% means that company has $1.67 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Telix Pharmaceuticals Limited:

  • The MRQ is 1.669. The company is just able to pay all its debts with equity.
  • The TTM is 1.669. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.669TTM1.6690.000
TTM1.669YOY1.675-0.006
TTM1.6695Y11.168-9.499
5Y11.16810Y5.678+5.490
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6690.393+1.276
TTM1.6690.439+1.230
YOY1.6750.435+1.240
3Y1.8580.462+1.396
5Y11.1680.463+10.705
10Y5.6780.511+5.167
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Telix Pharmaceuticals Limited generates.

  • Above 15 is considered overpriced butΒ always compareΒ Telix Pharmaceuticals Limited to theΒ Biotechnology industry mean.
  • A PE ratio of 160.09 means the investor is paying $160.09Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Telix Pharmaceuticals Limited:

  • The EOD is 95.741. Based on the earnings, the company is expensive. -2
  • The MRQ is 160.088. Based on the earnings, the company is expensive. -2
  • The TTM is 160.088. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD95.741MRQ160.088-64.347
MRQ160.088TTM160.0880.000
TTM160.088YOY-+160.088
TTM160.0885Y32.018+128.070
5Y32.01810Y16.009+16.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD95.741-2.447+98.188
MRQ160.088-2.328+162.416
TTM160.088-2.662+162.750
YOY--3.729+3.729
3Y53.363-3.747+57.110
5Y32.018-6.305+38.323
10Y16.009-6.948+22.957
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Telix Pharmaceuticals Limited:

  • The EOD is 531.209. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 888.232. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 888.232. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD531.209MRQ888.232-357.023
MRQ888.232TTM888.2320.000
TTM888.232YOY-+888.232
TTM888.2325Y177.646+710.586
5Y177.64610Y88.823+88.823
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD531.209-3.310+534.519
MRQ888.232-2.934+891.166
TTM888.232-3.859+892.091
YOY--4.296+4.296
3Y296.077-5.225+301.302
5Y177.646-8.425+186.071
10Y88.823-9.639+98.462
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Telix Pharmaceuticals Limited is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 14.06 means the investor is paying $14.06Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Telix Pharmaceuticals Limited:

  • The EOD is 8.411. Based on the equity, the company is overpriced. -1
  • The MRQ is 14.064. Based on the equity, the company is expensive. -2
  • The TTM is 14.064. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD8.411MRQ14.064-5.653
MRQ14.064TTM14.0640.000
TTM14.064YOY-+14.064
TTM14.0645Y2.813+11.251
5Y2.81310Y1.406+1.406
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.4112.233+6.178
MRQ14.0642.000+12.064
TTM14.0642.205+11.859
YOY-2.413-2.413
3Y4.6882.571+2.117
5Y2.8133.756-0.943
10Y1.4064.451-3.045
4.6.2. Total Gains per Share

2.4. Latest News of Telix Pharmaceuticals Limited

Does Telix Pharmaceuticals Limited still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Telix Pharmaceuticals Limited to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-09-11
23:09
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the FirmRead
2025-09-11
23:01
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsRead
2025-09-11
20:32
Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again – Hagens BermanRead
2025-09-10
01:00
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer DiagnosisRead
2025-09-08
02:22
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsRead
2025-09-04
13:43
Bragar Eagel & Squire, P.C. Is Investigating Agilon, Albany International, Fluor, and Telix and Encourages Investors to Contact the FirmRead
2025-08-21
20:38
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLXRead
2025-08-20
19:03
Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens BermanRead
2025-08-17
17:15
INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsΒ On Behalf of Investors of Telix Pharmaceuticals Limited – TLXRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in AUD. All numbers in thousands.

Summary
Total Assets1,516,431
Total Liabilities948,218
Total Stockholder Equity568,213
 As reported
Total Liabilities 948,218
Total Stockholder Equity+ 568,213
Total Assets = 1,516,431

Assets

Total Assets1,516,431
Total Current Assets918,564
Long-term Assets597,867
Total Current Assets
Cash And Cash Equivalents 710,346
Net Receivables 158,994
Inventory 38,144
Other Current Assets 11,080
Total Current Assets  (as reported)918,564
Total Current Assets  (calculated)918,564
+/-0
Long-term Assets
Property Plant Equipment 54,321
Goodwill 106,647
Long Term Investments 6,093
Intangible Assets 309,487
Long-term Assets Other 74,582
Long-term Assets  (as reported)597,867
Long-term Assets  (calculated)551,130
+/- 46,737

Liabilities & Shareholders' Equity

Total Current Liabilities330,912
Long-term Liabilities617,306
Total Stockholder Equity568,213
Total Current Liabilities
Short-term Debt 21,486
Short Long Term Debt 18,990
Accounts payable 68,698
Other Current Liabilities 180,903
Total Current Liabilities  (as reported)330,912
Total Current Liabilities  (calculated)290,077
+/- 40,835
Long-term Liabilities
Long term Debt 551,821
Capital Lease Obligations 10,637
Long-term Liabilities Other 30,406
Long-term Liabilities  (as reported)617,306
Long-term Liabilities  (calculated)592,864
+/- 24,442
Total Stockholder Equity
Retained Earnings -212,962
Accumulated Other Comprehensive Income 184,399
Other Stockholders Equity 596,776
Total Stockholder Equity (as reported)568,213
Total Stockholder Equity (calculated)568,213
+/-0
Other
Cash and Short Term Investments 710,346
Common Stock Shares Outstanding 345,188
Current Deferred Revenue11,248
Liabilities and Stockholders Equity 1,516,431
Net Debt -128,898
Net Invested Capital 1,139,024
Net Working Capital 587,652
Property Plant and Equipment Gross 63,609
Short Long Term Debt Total 581,448



6.2. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312011-12-312000-12-311999-12-31
> Total Assets 
0
9,394
11,776
18,542
17,735
17,814
18,613
51,094
76,708
102,608
164,442
109,813
260,591
398,302
1,516,431
1,516,431398,302260,591109,813164,442102,60876,70851,09418,61317,81417,73518,54211,7769,3940
   > Total Current Assets 
0
3,049
6,730
6,562
7,054
8,113
8,725
49,545
35,856
58,679
93,628
47,543
173,233
224,848
918,564
918,564224,848173,23347,54393,62858,67935,85649,5458,7258,1137,0546,5626,7303,0490
       Cash And Cash Equivalents 
0
2,994
1,092
55
756
750
841
48,759
25,771
44,598
77,945
22,037
116,329
123,237
710,346
710,346123,237116,32922,03777,94544,59825,77148,759841750756551,0922,9940
       Net Receivables 
0
55
0
2,391
3,255
3,961
4,327
489
8,971
13,009
14,191
20,845
31,140
79,535
158,994
158,99479,53531,14020,84514,19113,0098,9714894,3273,9613,2552,3910550
       Other Current Assets 
0
0
2,808
1,588
936
830
931
297
472
530
859
1,207
9,073
19,524
11,080
11,08019,5249,0731,2078595304722979318309361,5882,80800
   > Long-term Assets 
0
6,345
5,046
11,980
10,680
9,701
9,888
1,549
40,852
43,929
70,814
62,270
87,358
173,454
597,867
597,867173,45487,35862,27070,81443,92940,8521,5499,8889,70110,68011,9805,0466,3450
       Property Plant Equipment 
0
6,345
4,313
1,164
1,287
1,585
3,180
5
226
1,899
4,821
6,329
18,838
30,493
54,321
54,32130,49318,8386,3294,8211,89922653,1801,5851,2871,1644,3136,3450
       Goodwill 
0
0
732
746
865
1,020
1,032
332
3,140
4,224
4,224
4,097
5,519
4,847
106,647
106,6474,8475,5194,0974,2244,2243,1403321,0321,02086574673200
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
12,260
6,093
6,09312,2600000000000000
       Intangible Assets 
0
0
0
0
0
0
0
1,176
36,311
41,948
59,189
55,729
58,984
104,816
309,487
309,487104,81658,98455,72959,18941,94836,3111,1760000000
> Total Liabilities 
0
352
23,237
17,038
19,908
18,028
20,384
1,801
23,804
31,877
84,444
106,171
178,435
249,391
948,218
948,218249,391178,435106,17184,44431,87723,8041,80120,38418,02819,90817,03823,2373520
   > Total Current Liabilities 
0
352
17,879
12,532
7,437
11,487
14,260
1,468
8,242
10,625
19,956
37,982
85,556
157,408
330,912
330,912157,40885,55637,98219,95610,6258,2421,46814,26011,4877,43712,53217,8793520
       Short-term Debt 
0
0
504
2,483
2,107
1,414
4,141
345
1,133
490
767
632
641
1,559
21,486
21,4861,5596416327674901,1333454,1411,4142,1072,48350400
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
264
19
0
964
18,990
18,9909640192640000000000
       Accounts payable 
0
352
1,564
1,449
2,092
1,658
2,072
276
3,249
6,964
5,808
11,884
16,806
32,837
68,698
68,69832,83716,80611,8845,8086,9643,2492762,0721,6582,0921,4491,5643520
       Other Current Liabilities 
0
0
15,835
5,107
-294
5,237
5,391
847
3,860
3,171
10,146
19,323
55,849
100,509
180,903
180,903100,50955,84919,32310,1463,1713,8608475,3915,237-2945,10715,83500
   > Long-term Liabilities 
0
352
4,375
4,780
5,622
6,541
6,123
332
15,562
21,252
64,488
68,189
92,879
91,983
617,306
617,30691,98392,87968,18964,48821,25215,5623326,1236,5415,6224,7804,3753520
> Total Stockholder Equity
0
9,042
-2,246
1,504
-2,173
-214
-1,771
49,293
52,904
70,081
79,016
2,158
80,007
148,911
568,213
568,213148,91180,0072,15879,01670,08152,90449,293-1,771-214-2,1731,504-2,2469,0420
   Common Stock
0
15,121
-3,016
26
2
3
3
55,561
72,053
115,943
167,058
170,840
370,972
446,268
0
0446,268370,972170,840167,058115,94372,05355,56133226-3,01615,1210
   Retained Earnings Total Equity000000000000000
   Accumulated Other Comprehensive Income 
0
0
-3,412
-2,633
-6,353
-7,209
-7,784
109
1,059
2,212
4,919
4,789
-18,150
-33,692
184,399
184,399-33,692-18,1504,7894,9192,2121,059109-7,784-7,209-6,353-2,633-3,41200
   Capital Surplus 000000000000000
   Treasury Stock000000000000000
   Other Stockholders Equity 
0
0
4,182
20,822
28,962
38,608
39,094
2,109
43,022
53,988
0
0
0
0
596,776
596,776000053,98843,0222,10939,09438,60828,96220,8224,18200



6.3. Balance Sheets

Currency in AUD. All numbers in thousands.




6.4. Cash Flows

Currency in AUD. All numbers in thousands.




6.5. Income Statements

Currency in AUD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue783,207
Cost of Revenue-273,529
Gross Profit509,678509,678
 
Operating Income (+$)
Gross Profit509,678
Operating Expense-427,548
Operating Income82,13082,130
 
Operating Expense (+$)
Research Development194,637
Selling General Administrative121,653
Selling And Marketing Expenses85,473
Operating Expense427,548401,763
 
Net Interest Income (+$)
Interest Income10,862
Interest Expense-21,464
Other Finance Cost-15,472
Net Interest Income-26,074
 
Pretax Income (+$)
Operating Income82,130
Net Interest Income-26,074
Other Non-Operating Income Expenses-
Income Before Tax (EBT)56,056108,204
EBIT - interestExpense = 60,666
56,056
71,383
Interest Expense21,464
Earnings Before Interest and Taxes (EBIT)82,13077,520
Earnings Before Interest and Taxes (EBITDA)92,547
 
After tax Income (+$)
Income Before Tax56,056
Tax Provision-6,137
Net Income From Continuing Ops49,91949,919
Net Income49,919
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses701,077
Total Other Income/Expenses Net-26,07426,074
 

Technical Analysis of Telix Pharmaceuticals Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Telix Pharmaceuticals Limited. The general trend of Telix Pharmaceuticals Limited is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Telix Pharmaceuticals Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Telix Pharmaceuticals Limited Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Telix Pharmaceuticals Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 10.50 < 10.70 < 12.60.

The bearish price targets are: 8.93.

Know someone who trades $TLX? Share this with them.πŸ‘‡

Telix Pharmaceuticals Limited Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Telix Pharmaceuticals Limited. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Telix Pharmaceuticals Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Telix Pharmaceuticals Limited. The current macd is -0.9974661.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Telix Pharmaceuticals Limited price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Telix Pharmaceuticals Limited. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Telix Pharmaceuticals Limited price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Telix Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) ChartTelix Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Telix Pharmaceuticals Limited. The current adx is 25.27.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Telix Pharmaceuticals Limited shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Telix Pharmaceuticals Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Telix Pharmaceuticals Limited. The current sar is 10.82.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Telix Pharmaceuticals Limited Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Telix Pharmaceuticals Limited. The current rsi is 33.19. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Telix Pharmaceuticals Limited Daily Relative Strength Index (RSI) ChartTelix Pharmaceuticals Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Telix Pharmaceuticals Limited. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Telix Pharmaceuticals Limited price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Telix Pharmaceuticals Limited Daily Stochastic Oscillator ChartTelix Pharmaceuticals Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Telix Pharmaceuticals Limited. The current cci is -69.8303332.

Telix Pharmaceuticals Limited Daily Commodity Channel Index (CCI) ChartTelix Pharmaceuticals Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Telix Pharmaceuticals Limited. The current cmo is -33.73180759.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Telix Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) ChartTelix Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Telix Pharmaceuticals Limited. The current willr is -92.32876712.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Telix Pharmaceuticals Limited Daily Williams %R ChartTelix Pharmaceuticals Limited Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Telix Pharmaceuticals Limited.

Telix Pharmaceuticals Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Telix Pharmaceuticals Limited. The current atr is 0.52505554.

Telix Pharmaceuticals Limited Daily Average True Range (ATR) ChartTelix Pharmaceuticals Limited Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Telix Pharmaceuticals Limited. The current obv is -2,923,075.

Telix Pharmaceuticals Limited Daily On-Balance Volume (OBV) ChartTelix Pharmaceuticals Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Telix Pharmaceuticals Limited. The current mfi is 17.94.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Telix Pharmaceuticals Limited Daily Money Flow Index (MFI) ChartTelix Pharmaceuticals Limited Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Telix Pharmaceuticals Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-24BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-28ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-07-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-13MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-08-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-08-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-08-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-08-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-09-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-09-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-09-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Telix Pharmaceuticals Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Telix Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.186
Ma 20Greater thanMa 5010.516
Ma 50Greater thanMa 10012.666
Ma 100Greater thanMa 20014.836
OpenGreater thanClose9.160
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Telix Pharmaceuticals Limited with someone you think should read this too:
  • Are you bullish or bearish on Telix Pharmaceuticals Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Telix Pharmaceuticals Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Telix Pharmaceuticals Limited

I send you an email if I find something interesting about Telix Pharmaceuticals Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Telix Pharmaceuticals Limited.

Receive notifications about Telix Pharmaceuticals Limited in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.